EAM
Exome Asset Management Portfolio holdings
AUM
$110M
This Quarter Return
-6.4%
1 Year Return
+24.83%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$112M
AUM Growth
+$112M
(-16%)
Cap. Flow
-$14.9M
Cap. Flow
% of AUM
-13.34%
Top 10 Holdings %
Top 10 Hldgs %
39.5%
Holding
78
New
15
Increased
14
Reduced
14
Closed
24
Top Buys
| 1 |
AstraZeneca
AZN
|
$4.73M |
| 2 |
Cogent Biosciences
COGT
|
$3.72M |
| 3 |
Viridian Therapeutics
VRDN
|
$2.93M |
| 4 |
Regenxbio
RGNX
|
$2.9M |
| 5 |
Dyne Therapeutics
DYN
|
$2.7M |
Top Sells
| 1 |
Humana
HUM
|
$4.58M |
| 2 |
Relay Therapeutics
RLAY
|
$4.46M |
| 3 |
Apellis Pharmaceuticals
APLS
|
$3.81M |
| 4 |
Bristol-Myers Squibb
BMY
|
$3.69M |
| 5 |
Boston Scientific
BSX
|
$3.62M |
Sector Composition
| 1 | Healthcare | 98.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
BridgeBio Pharma
BBIO
$9.89B
| $5.72M | 5.09% | 165,496 -81,204 | -33% | -$2.81M |
|
2
Guardant Health
GH
$8.41B
| $5.42M | 4.82% | 127,182 -20,618 | -14% | -$878K |
|
3
Geron
GERN
$893M
| $5.11M | 4.54% | 3,215,457 +1,654,305 | +106% | +$2.63M |
|
|
4
AstraZeneca
AZN
$248B
| $4.73M | 4.2% | +32,534 | New | +$4.73M |
|
5
Cytokinetics
CYTK
$4.23B
| $4.16M | 3.7% | 103,483 +37,600 | +57% | +$1.51M |
|
6
Syndax Pharmaceuticals
SNDX
$1.41B
| $4.14M | 3.68% | 337,198 +18,298 | +6% | +$225K |
|
7
Ionis Pharmaceuticals
IONS
$6.79B
| $4.09M | 3.64% | 135,616 +74,249 | +121% | +$2.24M |
|
8
Eli Lilly
LLY
$657B
| $3.86M | 3.43% | 4,673 -3,574 | -43% | -$2.95M |
|
|
9
Cogent Biosciences
COGT
$1.69B
| $3.72M | 3.31% | +621,678 | New | +$3.72M |
|
10
Intuitive Surgical
ISRG
$170B
| $3.15M | 2.8% | 6,358 -1,069 | -14% | -$529K |
|
11
Soleno Therapeutics
SLNO
$3.6B
| $3.1M | 2.76% | 43,441 -33,844 | -44% | -$2.42M |
|
12
Akero Therapeutics
AKRO
$3.74B
| $3.09M | 2.75% | 76,379 +7,771 | +11% | +$315K |
|
13
Disc Medicine
IRON
$2.07B
| $3.06M | 2.72% | 61,656 -7,416 | -11% | -$368K |
|
|
14
Viridian Therapeutics
VRDN
$1.5B
| $2.93M | 2.6% | +217,294 | New | +$2.93M |
|
|
15
Regenxbio
RGNX
$451M
| $2.9M | 2.58% | +405,281 | New | +$2.9M |
|
16
Replimune Group
REPL
$422M
| $2.87M | 2.56% | 294,846 +240,108 | +439% | +$2.34M |
|
17
Scholar Rock
SRRK
$3.14B
| $2.71M | 2.41% | 84,339 +6,900 | +9% | +$222K |
|
|
18
Dyne Therapeutics
DYN
$1.92B
| $2.7M | 2.4% | +258,391 | New | +$2.7M |
|
19
Natera
NTRA
$23.1B
| $2.64M | 2.34% | 18,650 -3,800 | -17% | -$537K |
|
20
89bio
ETNB
$1.34B
| $2.57M | 2.29% | 353,882 +128,559 | +57% | +$935K |
|
21
Penumbra
PEN
$10.6B
| $2.41M | 2.14% | 9,000 | – | – |
|
22
Savara
SVRA
$567M
| $2.32M | 2.06% | 836,397 +136,699 | +20% | +$379K |
|
23
AnaptysBio
ANAB
$569M
| $2.17M | 1.93% | +116,623 | New | +$2.17M |
|
24
Travere Therapeutics
TVTX
$1.56B
| $2.11M | 1.88% | +118,017 | New | +$2.11M |
|
|
CNTA
25
Centessa Pharmaceuticals
CNTA
$2.25B
| $2.05M | 1.82% | 142,744 +5,028 | +4% | +$72.3K |
|